49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01683695 (ClinicalTrials.gov)	June 2012	14/3/2012	Safety Study of AMG 557 in Subjects With Lupus Arthritis	A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis	Lupus Arthritis, Systemic Lupus Erythematosus	Drug: AMG 557;Drug: Matching Placebo	Amgen	NULL	Completed	18 Years	65 Years	All	20	Phase 1	United States;Australia;Denmark;France;Germany;Malaysia;Taiwan;United Kingdom;Singapore
2	NCT00774943 (ClinicalTrials.gov)	December 2008	16/10/2008	A Study of AMG 557 in Adults With Systemic Lupus Erythematosus	A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: AMG 557	Amgen	NULL	Completed	18 Years	70 Years	Both	58	Phase 1	United States;Canada
3	NCT02391259 (ClinicalTrials.gov)	November 2006	6/1/2015	A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus	Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: AMG 557;Drug: Placebo	Amgen	NULL	Completed	18 Years	70 Years	Both	57	Phase 1	United States;United Kingdom